BridgeBio Pharma, Inc. Long-term Debt, Gross
BridgeBio Pharma, Inc. (BBIO) had Long-term Debt, Gross of $92.50 million as of 2020-12-31, per its 10-K filed 2022-02-25.
Discontinued › Notes
us-gaap:DebtInstrumentCarryingAmount · last filed 2022-02-25
- 2020-12-31: Long-term Debt, Gross $92.50M.
- 2019-12-31: Long-term Debt, Gross $75.00M.
| Period end | Long-term Debt, Gross |
|---|---|
| 2020-12-31 | $92.50M 10-K · filed 2022-02-25 |
| 2019-12-31 | $75.00M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |